S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Mayne Pharma Group Stock Forecast, Price & News

+0.01 (+4.47 %)
(As of 10/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume10,150 shs
Average Volume17,054 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MAYNF News and Ratings via Email

Sign-up to receive the latest news and ratings for Mayne Pharma Group and its competitors with MarketBeat's FREE daily newsletter.

Mayne Pharma Group logo

About Mayne Pharma Group

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment involves in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty brands segments includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment offers manufacturing and selling of branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.


See More Headlines

Industry, Sector and Symbol

Drug Manufacturers - Major
Current Symbol
Year Founded

Sales & Book Value

Annual Sales





Next Earnings Date
Not Optionable


Overall MarketRank

1.58 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Mayne Pharma Group (OTCMKTS:MAYNF) Frequently Asked Questions

Is Mayne Pharma Group a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mayne Pharma Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Mayne Pharma Group stock.
View analyst ratings for Mayne Pharma Group
or view top-rated stocks.

What stocks does MarketBeat like better than Mayne Pharma Group?

Wall Street analysts have given Mayne Pharma Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mayne Pharma Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Mayne Pharma Group?

Mayne Pharma Group saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 1,041,500 shares, a decline of 27.9% from the September 15th total of 1,445,000 shares. Based on an average trading volume of 4,500 shares, the short-interest ratio is presently 231.4 days.
View Mayne Pharma Group's Short Interest

How has Mayne Pharma Group's stock price been impacted by Coronavirus (COVID-19)?

Mayne Pharma Group's stock was trading at $0.1962 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MAYNF stock has increased by 19.2% and is now trading at $0.2339.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MAYNF?

1 brokerages have issued 12-month price targets for Mayne Pharma Group's stock. Their forecasts range from $0.35 to $0.35. On average, they expect Mayne Pharma Group's stock price to reach $0.35 in the next year. This suggests a possible upside of 49.7% from the stock's current price.
View analysts' price targets for Mayne Pharma Group
or view top-rated stocks among Wall Street analysts.

Who are Mayne Pharma Group's key executives?

Mayne Pharma Group's management team includes the following people:
  • Scott Richards, Chief Executive Officer, MD & Executive Director
  • Peter Paltoglou, Chief Financial Officer
  • Keith Moore, Vice President-Research & Development
  • Gerard G. Nahum, Chief Medical Officer
  • Kate Hall, Executive Vice President & General Counsel

What is Mayne Pharma Group's stock symbol?

Mayne Pharma Group trades on the OTCMKTS under the ticker symbol "MAYNF."

How do I buy shares of Mayne Pharma Group?

Shares of MAYNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mayne Pharma Group's stock price today?

One share of MAYNF stock can currently be purchased for approximately $0.23.

How many employees does Mayne Pharma Group have?

Mayne Pharma Group employs 780 workers across the globe.

What is Mayne Pharma Group's official website?

The official website for Mayne Pharma Group is www.maynepharma.com.

Where are Mayne Pharma Group's headquarters?

Mayne Pharma Group is headquartered at 1538 Main North Road, Salisbury, South Australia.

How can I contact Mayne Pharma Group?

Mayne Pharma Group's mailing address is 1538 Main North Road, Salisbury, South Australia. The company can be reached via phone at (188) 209-2666.

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.